Document Type : Full Research Paper

Authors

• Hamid Khaloozadeh ¹
• Pedram Yazdanbakhsh ²
• Fateme Homaei Shandiz ³

¹ Associate Professor, Control Engineering School, K.N. Toosi University of Technology

² MSc. Graduate in Control Engineering, Ferdowsi University

³ Associate Professor, Department of' Radiation-Oncology, Medical School, Mashhad University of Medical Sciences

Abstract

The optimal doses of Doxorubicin and Cyclophosphamide (AC) regimen in pre-operation Neoadjuvant chemotherapy for the patients suffering from stage III breast cancer were investigated. The major benefit of Neoadjuvant chemotherapy is that it can shrink large cancers so that they are small enough to be removed by lumpectomy instead of mastectomy. The optimal regimen designed in this paper was based on the special conditions that every patient had been treated by her/his own physician and the resistance of tumor cells. With respect to these regimen that can achieve non equivalent doses of drug in treatment times for neoadjuvant chemotherapy. The purpose of treating the patients with cancer in neoadjuvant chemotherapy could be either destroying the cancer cells or preserving the normal cell populations in the best way, or different cases between these two situations. In this article, by solving a cost function involved with the dynamics of both cancer cells and normal cells - using the appropriate weighting coefficients suggested by the treating physician- the optimal doses of AC drugs for the patients suffering from breast cancer at stage III were computed by the proposed optimal controller. 

Keywords

• chemotherapy
• Neoadjuvant chemotherapy
• Stage III breast cancer
• Growth models
• Optimal drug programming

Main Subjects

• Cell Biomechanics / Cell Mechanics / Mechanobiology
• Pharmaceutical Engineering / Biopharmaceuticals